Journal
BIOMEDICINES
Volume 11, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines11112903
Keywords
Basal cell carcinoma; basosquamous carcinoma; Squamous Cell Carcinoma; immunotherapy; Cemiplimab; hedgehog inhibitors; Sonidegib
Ask authors/readers for more resources
This study describes a successful treatment of a patient with BSC. The efficacy of Cemiplimab against BSC and other histopathological subtypes of BCC has not been fully elucidated, and the role of sequential or combination therapy with Cemiplimab and HHI in the management of BSC needs further investigation.
Basal cell carcinoma (BCC) is a skin cancer with low local aggressiveness and a low tendency to metastasize. Basosquamous Carcinoma (BSC) represents an aggressive histological subtype of BCC with intermediate features between Squamous Cell Carcinoma (SCC) and BCC. Cemiplimab is currently approved as first-line therapy in SCC and second-line therapy in BCC patients who have progressed on or are intolerant of a Hedgehog pathway Inhibitor (HHI). Our study describes the case of a 59-year-old man with BSC who was successfully treated with 5 cycles of Cemiplimab as first-line therapy and Sonidegib as second-line therapy. Currently, the efficacy of Cemiplimab against BSC and other histopathological subtypes of BCC has not been fully elucidated, as has the role of sequential or combination therapy with Cemiplimab and HHI in the management of BSC. The aim of this case report is to highlight the need to outline the use of checkpoint inhibitors in BCCs and focus attention on the synergistic role of Cemiplimab and HHIs in such a controversial entity as BSC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available